USNA vs. STVN: Which Stock Is the Better Value Option?

A comparative analysis by Zacks identifies USANA Health Sciences (USNA) as a superior value option over Stevanato Group (STVN) within the Medical - Drugs sector. USNA holds a Zacks Rank of #2 (Buy) compared to STVN's #3 (Hold), indicating a stronger earnings outlook. Valuation metrics further support this, with USNA exhibiting a significantly lower forward P/E of 11.65 versus STVN's 46.19, a PEG ratio of 0.97 against STVN's 2.63, and a P/B ratio of 1.07 compared to STVN's 5.04, leading to USNA earning a Value grade of A while STVN received a C.

Analysis

A comparative fundamental analysis within the Medical - Drugs sector positions USANA Health Sciences (USNA) as a more compelling value investment than Stevanato Group (STVN). The primary driver for this assessment is the divergence in earnings outlook and valuation metrics. USNA holds a Zacks Rank of #2 (Buy), indicating a stronger trend in positive earnings estimate revisions compared to STVN's #3 (Hold) rank. This superior outlook is complemented by a significant valuation discount across multiple key figures. Specifically, USNA's forward P/E ratio stands at 11.65, nearly four times lower than STVN's 46.19. Furthermore, USNA's PEG ratio of 0.97 suggests its stock price is reasonably valued relative to its growth expectations, contrasting sharply with STVN's PEG of 2.63. The disparity is also evident in the price-to-book (P/B) ratio, where USNA's 1.07 is substantially more attractive than STVN's 5.04. Collectively, these quantitative factors result in USNA earning a top-tier 'A' grade for Value in the Zacks Style Scores system, while STVN receives a 'C'.

Key Decisions for Investors

• Value-oriented investors should consider USANA Health Sciences (USNA) as a potential long position, given its 'Buy' rank and significant valuation discount relative to its peer, Stevanato Group.
• Investors holding Stevanato Group (STVN) for its value characteristics should reassess their position, as its high forward P/E of 46.19 and P/B of 5.04 indicate a rich valuation with potentially limited upside on a relative value basis.
• Portfolio managers should monitor the earnings estimate revision trends for both companies, as the current divergence, reflected in their respective Zacks Ranks, is a key driver of this value-based thesis.